Skip to main content
    A

    argenx NV ADR (ARGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $960.04
    -21.29 (-2.17%)

    Market Cap: $60.37B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    argenx NV ADR (ARGX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to argenx NV ADR are BeOne Medicines AG (ONC), Genmab AS (GMAB) and Regeneron Pharmaceuticals (REGN). argenx NV ADR trades at 33.5x earnings, against a median of 24.7x for the 6 of these companies with a P/E. By market cap, argenx NV ADR ranks 4th of the 13 companies on this page; Vertex Pharmaceuticals (VRTX) is the largest at $136.56B.

    Peer Comparison

    ARGX's revenue growth of 52.1% is above the peer median of 22.6%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    argenx NV ADR (ARGX)$60.37B33.5x6.1x31.7%N/A52.1%0.00%
    BeOne Medicines AG (ONC)$47.58B50.0x18.7x13.9%7.5%33.8%0.00%
    Genmab AS (GMAB)$31.67B35.8x19.2x17.0%4.8%16.1%0.00%
    Regeneron Pharmaceuticals Inc (REGN)$98.84B18.4x5.7x28.5%13.7%36.3%0.39%
    Moderna Inc (MRNA)$90.38BN/A34.2x-110.5%-28.9%29.2%0.00%
    Revolution Medicines Inc (RVMD)$37.27BN/A181.6x0.0%-52.1%-95.2%0.00%
    Insmed Inc (INSM)$26.58BN/A17.7x-39.9%-44.2%268.4%0.00%
    Royalty Pharma Plc (RPRX)$39.85B12.9x11.7x25.7%7.6%13.3%1.37%
    Roivant Sciences Ltd (ROIV)$28.64BN/A679.3x0.0%N/A2136.0%0.00%
    Ascendis Pharma AS (ASND)$18.06BN/A13.5x72.9%12.4%73.0%0.00%
    Exelixis Inc (EXEL)$16.84B19.3x6.9x35.4%N/A10.2%0.00%
    Vertex Pharmaceuticals Inc (VRTX)$136.56B30.0x10.5x30.7%14.2%11.8%0.00%
    Apogee Therapeutics, Inc. Common Stock (APGE)$10.22BN/AN/A0.0%N/A0.0%0.00%
    Peer median$34.47B24.7x17.7x15.4%7.5%22.6%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to argenx NV ADR, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    BeOne Medicines AG (ONC)
    BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe...
    ONC competitors
    Genmab AS (GMAB)
    Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
    GMAB competitors
    Regeneron Pharmaceuticals Inc (REGN)
    Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.
    REGN competitors
    Moderna Inc (MRNA)
    Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology...
    MRNA competitors
    Revolution Medicines Inc (RVMD)
    Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted...
    RVMD competitors
    Insmed Inc (INSM)
    Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases.
    INSM competitors
    Royalty Pharma Plc (RPRX)
    Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States.
    RPRX competitors
    Roivant Sciences Ltd (ROIV)
    Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive...
    ROIV competitors
    Ascendis Pharma AS (ASND)
    Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
    ASND competitors
    Exelixis Inc (EXEL)
    Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development...
    EXEL competitors
    Vertex Pharmaceuticals Inc (VRTX)
    Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
    VRTX competitors
    Apogee Therapeutics, Inc. Common Stock (APGE)
    Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD)...

    Frequently Asked Questions About ARGX

    Who are argenx NV ADR's main competitors?

    The companies most similar to argenx NV ADR include BeOne Medicines AG (ONC), Genmab AS (GMAB), Regeneron Pharmaceuticals (REGN), Moderna (MRNA) and Revolution Medicines (RVMD), listed from the closest match.

    Who is argenx NV ADR's biggest competitor?

    Vertex Pharmaceuticals (VRTX) is the largest of the similar companies at $136.56B; BeOne Medicines AG (ONC) is the closest match by business profile, size, sector and industry.

    How does ARGX stock compare with its competitors?

    ARGX's P/E is 33.5x against a peer median of 24.7x; its P/S is 6.1x against a peer median of 17.7x; its net margin is 31.7% against a peer median of 15.4%.

    Which of argenx NV ADR's competitors pays a higher dividend?

    argenx NV ADR pays no dividend. Royalty Pharma Plc (RPRX) and Regeneron Pharmaceuticals (REGN) have higher forward dividend yields; Royalty Pharma Plc (RPRX) has the highest at 1.37%.

    Is argenx NV ADR bigger than its competitors?

    No. argenx NV ADR is 4th by market cap among the 13 companies on this page; the largest is Vertex Pharmaceuticals (VRTX) at $136.56B.